tetano
Editor, Senior Moderator
Viruses
. 2022 Aug 1;14(8):1702.
doi: 10.3390/v14081702.
Long-Term Outcomes after Vaccine-Induced Thrombotic Thrombocytopenia
Victoria Panagiota[SUP] 1 [/SUP], Christiane Dobbelstein[SUP] 1 [/SUP], Sonja Werwitzke[SUP] 1 [/SUP], Arnold Ganser[SUP] 1 [/SUP], Nina Cooper[SUP] 2 [/SUP], Ulrich J Sachs[SUP] 2 [/SUP], Andreas Tiede[SUP] 1 [/SUP]
Affiliations
Abstract
Vaccine-induced thrombotic thrombocytopenia (VITT), or thrombosis with thrombocytopenia syndrome (TTS), is a rare but serious complication of adenovirus-based vaccines against severe respiratory syndrome coronavirus 2 (SARS-CoV-2). Observation of long-term outcomes is important to guide treatment of affected patients. This single-center consecutive cohort study included all patients diagnosed based on (1) vaccination 4 to 21 days before symptom onset, (2) signs or symptoms of venous or arterial thrombosis, (3) thrombocytopenia < 150/nL, (4) positive anti-platelet factor 4 (PF4) antibody, and (5) elevated D-Dimer > 4 times the upper limit of normal. Nine patients were enrolled. Acute management consisted of parenteral anticoagulants, corticosteroids, intravenous immunoglobulin (IVIG), and/or eculizumab. Eculizumab was successfully used in two patients with recurrent thromboembolic events after IVIG. Direct oral anticoagulants were given after hospital discharge. Median follow-up duration was 300 days (range 153 to 380). All patients survived the acute phase of the disease and were discharged from hospital. One patient died from long-term neurological sequelae of cerebral venous sinus thrombosis 335 days after diagnosis. Eight out of nine patients were alive at last follow-up, and seven had fully recovered. Anti-PF4 antibodies remained detectable for at least 12 weeks after diagnosis, and D-Dimer remained elevated in some patients despite oral anticoagulation. No recurrent thromboembolic events, other signs of VITT relapse, or bleeding complications occurred after discharge. In conclusion, VITT appears to be a highly prothrombotic condition. IVIG is not always successful, and eculizumab may be considered a rescue agent. Long-term management with direct oral anticoagulants appears to be safe and effective.
Keywords: AZD1222; COVID-19; ChAdOx1 nCoV-19; SARS-CoV-2; cerebral venous sinus thrombosis; cohort studies; platelet activation; thrombosis; vaccination.
. 2022 Aug 1;14(8):1702.
doi: 10.3390/v14081702.
Long-Term Outcomes after Vaccine-Induced Thrombotic Thrombocytopenia
Victoria Panagiota[SUP] 1 [/SUP], Christiane Dobbelstein[SUP] 1 [/SUP], Sonja Werwitzke[SUP] 1 [/SUP], Arnold Ganser[SUP] 1 [/SUP], Nina Cooper[SUP] 2 [/SUP], Ulrich J Sachs[SUP] 2 [/SUP], Andreas Tiede[SUP] 1 [/SUP]
Affiliations
- PMID: 36016324
- DOI: 10.3390/v14081702
Abstract
Vaccine-induced thrombotic thrombocytopenia (VITT), or thrombosis with thrombocytopenia syndrome (TTS), is a rare but serious complication of adenovirus-based vaccines against severe respiratory syndrome coronavirus 2 (SARS-CoV-2). Observation of long-term outcomes is important to guide treatment of affected patients. This single-center consecutive cohort study included all patients diagnosed based on (1) vaccination 4 to 21 days before symptom onset, (2) signs or symptoms of venous or arterial thrombosis, (3) thrombocytopenia < 150/nL, (4) positive anti-platelet factor 4 (PF4) antibody, and (5) elevated D-Dimer > 4 times the upper limit of normal. Nine patients were enrolled. Acute management consisted of parenteral anticoagulants, corticosteroids, intravenous immunoglobulin (IVIG), and/or eculizumab. Eculizumab was successfully used in two patients with recurrent thromboembolic events after IVIG. Direct oral anticoagulants were given after hospital discharge. Median follow-up duration was 300 days (range 153 to 380). All patients survived the acute phase of the disease and were discharged from hospital. One patient died from long-term neurological sequelae of cerebral venous sinus thrombosis 335 days after diagnosis. Eight out of nine patients were alive at last follow-up, and seven had fully recovered. Anti-PF4 antibodies remained detectable for at least 12 weeks after diagnosis, and D-Dimer remained elevated in some patients despite oral anticoagulation. No recurrent thromboembolic events, other signs of VITT relapse, or bleeding complications occurred after discharge. In conclusion, VITT appears to be a highly prothrombotic condition. IVIG is not always successful, and eculizumab may be considered a rescue agent. Long-term management with direct oral anticoagulants appears to be safe and effective.
Keywords: AZD1222; COVID-19; ChAdOx1 nCoV-19; SARS-CoV-2; cerebral venous sinus thrombosis; cohort studies; platelet activation; thrombosis; vaccination.